Therapeutic Potential of Cannabinoids in Glaucoma

被引：11

作者：

Lindner, Theresa ^{[1
]}

Schmidl, Doreen ^{[1
]}

Peschorn, Laura ^{[1
]}

Pai, Viktoria ^{[1
]}

Popa-Cherecheanu, Alina ^{[2
,3
]}

Chua, Jacqueline ^{[4
,5
]}

Schmetterer, Leopold ^{[1
,4
,5
,6
,7
,8
,9
]}

Garhoefer, Gerhard ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria

[2] Emergency Univ Hosp, Dept Ophthalmol, Bucharest 050098, Romania

[3] Carol Davila Univ Med & Pharm, Bucharest 020021, Romania

[4] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 169856, Singapore

[5] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore 169857, Singapore

[6] Nanyang Technol Univ, SERI NTU Adv Ocular Engn STANCE, Singapore 639798, Singapore

[7] Nanyang Technol Univ, Sch Chem Chem Engn & Biotechnol, Singapore 637459, Singapore

[8] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria

[9] Inst Mol & Clin Ophthalmol, Basel, Switzerland

来源：

PHARMACEUTICALS | 2023年 / 16卷 / 08期

基金：

奥地利科学基金会;

关键词：

cannabinoids; cannabinoid receptors; endocannabinoid system; glaucoma; intraocular pressure; neuroprotection; ocular hemodynamics; ocular blood flow; OCULAR BLOOD-FLOW; PRESSURE-INDUCED ISCHEMIA; OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; OPTIC-NERVE; ENDOCANNABINOID SYSTEM; CB1; RECEPTORS; TOPICAL DELTA-9-TETRAHYDROCANNABINOL; ENDOTHELIAL DYSFUNCTION; INTRACELLULAR CA2+;

D O I：

10.3390/ph16081149

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Glaucoma is a leading cause of irreversible blindness worldwide. To date, intraocular pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated patients, the disease can progress. Cannabinoids, which have been known to lower IOP since the 1970s, have been shown to have beneficial effects in glaucoma patients beyond their IOP-lowering properties. In addition to the classical cannabinoid receptors CB(1 )and CB2, knowledge of non-classical cannabinoid receptors and the endocannabinoid system has increased in recent years. In particular, the CB2 receptor has been shown to mediate anti-inflammatory, anti-apoptotic, and neuroprotective properties, which may represent a promising therapeutic target for neuroprotection in glaucoma patients. Due to their vasodilatory effects, cannabinoids improve blood flow to the optic nerve head, which may suggest a vasoprotective potential and counteract the altered blood flow observed in glaucoma patients. The aim of this review was to assess the available evidence on the effects and therapeutic potential of cannabinoids in glaucoma patients. The pharmacological mechanisms underlying the effects of cannabinoids on IOP, neuroprotection, and ocular hemodynamics have been discussed.

引用

页数：22

共 188 条

[1]

Accelerated Cure Project for Multiple Sclerosis, SAT ROAD FDA APPR

[2] Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma [J].